Publikationen, an denen er mitarbeitet Arnon Nagler (15)

2019

  1. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 253-264

  2. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

    The Lancet Haematology, Vol. 6, Núm. 9, pp. e459-e469

2018

  1. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

    Nature Medicine, Vol. 24, Núm. 12, pp. 1867-1876

2017

  1. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

    Leukemia, Vol. 31, Núm. 1, pp. 107-114

  2. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

    Blood, Vol. 130, Núm. 24, pp. 2610-2618

2016

  1. Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

    Cancer, Vol. 122, Núm. 13, pp. 2050-2056

2011

  1. Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: Effects of adverse prognostic factors on outcome

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, Núm. 1, pp. 44-49

2008

  1. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation

    Haematologica, Vol. 93, Núm. 9, pp. 1343-1350

  2. Erratum: Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma (Leukemia (2008) vol. 22 (1250-1255) 10.1038/leu.2008.88)

    Leukemia

  3. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment

    Clinical Lymphoma and Myeloma, Vol. 8, Núm. 6, pp. 352-355

2007

  1. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression

    Journal of Clinical Oncology, Vol. 25, Núm. 25, pp. 3892-3901

2006

  1. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma

    Bone Marrow Transplantation, Vol. 37, Núm. 12, pp. 1135-1141

  2. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma [8]

    Blood

2004

  1. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation

    Blood, Vol. 103, Núm. 11, pp. 4056-4061

  2. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma

    Biology of Blood and Marrow Transplantation, Vol. 10, Núm. 10, pp. 698-708